Senseonics Reports Record 2025 Revenue, Strong Patient Growth, and Projects 65-76% Revenue Increase for 2026

summarizeSummary

Senseonics Holdings announced preliminary record revenues for Q4 and full-year 2025, significant patient growth, and provided robust 2026 revenue guidance projecting 65-76% growth, driven by strategic commercialization changes and product development.

check_boxKey Events

• Record 2025 Revenue

  Reported preliminary unaudited revenue of approximately $14.2 million for Q4 2025 (71% YOY increase) and $35.2 million for full-year 2025 (57% YOY increase), marking the largest quarterly and annual revenue in company history.

• Strong 2026 Revenue Guidance

  Projected full-year 2026 global net revenue to be between $58 million and $62 million, representing a substantial increase of 65% to 76% over 2025 revenue, with an expected gross margin of approximately 50%.

• Significant Patient Growth

  Achieved 103% new patient growth in the U.S. during Q4 2025 compared to Q4 2024, driven by direct-to-consumer marketing efforts.

• Strategic Commercialization Shift

  Executed agreements with Ascensia Diabetes Care to take over commercialization and distribution of Eversense® in the U.S. starting January 1, 2026, which is expected to lead to higher revenue and improved gross margins.

auto_awesomeAnalysis

The filing indicates strong operational momentum and a positive outlook for Senseonics. The preliminary 2025 revenues represent the highest in company history, coupled with substantial patient base expansion. The 2026 revenue guidance, projecting significant year-over-year growth, suggests a strong trajectory, partly due to the strategic transition of commercialization rights for Eversense. Additionally, the FDA IDE approval for the Gemini sensor pivotal trial marks a key advancement in product development, reinforcing the company's long-term potential.